Jean-Frederic Colombel, MD, offers insights into subcutaneous infliximab-dyyb injection, detailing its administration and approved indications for ulcerative colitis and Crohn's disease.
Back
Reducing Treatment Burden in IBD with At-Home Therapy Options
Jean-Frederic Colombel, MD, provides a comprehensive overview of subcutaneous infliximab-dyyb injection for ulcerative colitis and Crohn's disease, analyzing clinical trial data, , discussing patient selection for this therapy, and evaluating its place in the evolving inflammatory bowel disease treatment landscape.
Reducing Treatment Burden in IBD with At-Home Therapy Options
Episodes
All
All
A key opinion leader analyzes the clinical remission and endoscopic response data from the LIBERTY CD and LIBERTY UC trials for subcutaneous infliximab-dyyb injection, contrasts it with intravenous infliximab, and evaluates the drug's safety and efficacy profile.
Jean-Frederic Colombel, MD, examines considerations for transitioning patients from intravenous to subcutaneous infliximab and evaluates the role of subcutaneous infliximab within the evolving landscape of inflammatory bowel disease treatments.
Advertisement
Advertisement
Trending on HCPLive
1
Omalizumab-Facilitated OIT Enables Maintenance Dosing in Food Allergy
2
After Sickle Cell Gene Therapy, What Comes Next?
3
VESALIUS-CV: Evolocumab Prevents Cardiovascular Disease in High-Risk Diabetes
4
New Liver Cancer BEACON-HCC Framework Shows 96.6% Concordance in Pilot
5